Kiadis Pharma announces change to management board

Amsterdam, The Netherlands, December 11, 2019 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that Scott A. Holmes, the Company’s chief financial officer and member of the Company’s management board, is stepping down to pursue other opportunities. Mr. Holmes’ resignation will be effective December 31, 2019.

“I want to thank Scott for his contributions to Kiadis; on behalf of the supervisory board and myself, we wish Scott well in his future endeavors,” Arthur Lahr, CEO of Kiadis commented. “Following our recent restructuring, Kiadis is an earlier stage company with a strong management team to advance our Company through our next phase of growth. As such, we do not plan to fill the CFO role as Scott’s responsibilities can be taken over by other management team members, specifically Amy Sullivan and Paul van Hagen.”

Ms. Sullivan joined Kiadis in January 2019 as SVP, corporate affairs and has been promoted to Kiadis’ chief strategy officer responsible for fundraising, investor relations, public affairs and corporate communications. Mr. van Hagen joined Kiadis in 2018 as VP, finance, has been promoted to SVP finance, and will continue to be responsible for the finance function.   

About Kiadis
Founded in 1997, Kiadis Pharma is building a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with life-threatening diseases. With headquarters in Amsterdam, the Netherlands, and offices and activities across the United States, Kiadis Pharma is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.

Kiadis Pharma is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at kiadis.com .

Kiadis Contacts:

Kiadis Pharma: Maryann Cimino, Manager, Corporate Affairs Tel: +1 (617) 710-7305 m.cimino@kiadis.com

Optimum Strategic Communications: Mary Clark, Supriya Mathur, Hollie Vile Tel: +44 203 950 9144 David Brilleslijper (Amsterdam) Tel: +31 610 942 514 kiadis@optimumcomms.com

Forward Looking Statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s officers’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or projections, or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the anticipated or implied developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.